Editorial comment on "Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort"

Affiliations

Editorial

Sherif Mehralivand. Eur Radiol. 2021 Mar.

. 2021 Mar;31(3):1642-1643.

doi: 10.1007/s00330-020-07589-9. Epub 2021 Jan 8.

¹ Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. sherif.mehralivand@mail.de.

No abstract available

Comment on

Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort.
Giganti F, Stabile A, Stavrinides V, Osinibi E, Retter A, Orczyk C, Panebianco V, Trock BJ, Freeman A, Haider A, Punwani S, Allen C, Kirkham A, Emberton M, Moore CM. Giganti F, et al. Eur Radiol. 2021 Mar;31(3):1644-1655. doi: 10.1007/s00330-020-07256-z. Epub 2020 Sep 30. Eur Radiol. 2021. PMID: 33000302 Free PMC article.

1. Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272–277 - DOI
1. Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. https://doi.org/10.1056/NEJMoa1801993
1. Stamatakis L, Siddiqui MM, Nix JW et al (2013) Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 119:3359–3366 - DOI
1. Klotz L, Pond G, Loblaw A et al (2019) Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol. https://doi.org/10.1016/j.eururo.2019.10.007
1. Moore CM, Giganti F, Albertsen P et al (2017) Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations-a report of a European School of Oncology Task Force. Eur Urol 71:648–655 - DOI